Quest Diagnostics stock

DGX · NYSE · USD

Compare Quest Diagnostics
$261.68Change from previous close: +0.80%Absolute change: +$2.08

Close · November 16, 2026

Price history

+40.54% over the period

1 year: from $186.19 (November 17, 2025) to $261.68 (November 16, 2026), +40.54%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$261.68
October 30, 2026$251.82
September 30, 2026$233.07
August 31, 2026$240.30
July 31, 2026$233.01
June 30, 2026$211.95
May 29, 2026$194.90
April 30, 2026$194.20
March 31, 2026$195.98
February 27, 2026$211.91
January 30, 2026$187.03
December 31, 2025$173.53
November 28, 2025$189.18
November 17, 2025$186.19

At a glance

  • The company

    Provides diagnostic testing and information services including clinical laboratory testing, pathology, drug testing and risk assessment for healthcare providers, payers, employers and insurers

  • Latest results

    Quarter to September 30, 2026 · EPS $3.00 (estimate $2.87)

TickerLandia's take on Quest Diagnostics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$171.18
52-wk high$262.00

−0.12% from the 52-week high

Analysts · 17 analysts

Average target$257.27−1.69% vs. price

Buy 9 · Hold 8 · Sell 0 · Buy

TickerLandia Fingerprint: Quest Diagnostics

Compared with similar companies: very low risk and very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Quest Diagnostics is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Quest Diagnostics's P/E today is 29.9, above the median of its last 10 fiscal years (18.2; between 11.1 and 20.4 from 2016 to 2025). Quest Diagnostics's P/E (trailing 12 months): 25.9, −28% against the median of a group of 9 similar companies (36.1).

P/E compared with its history

Compared with 9 similar companies

Quest Diagnostics's metrics compared with similar companies
MetricQuest DiagnosticsPosition in the groupBand
P/E (trailing 12 months)25.9Low
Forward P/E21.7Middle
Operating margin14.9%Middle
ROE15.3%Middle
Debt/equity0.80Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Quest Diagnostics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.1B

Latest quarter · Q3 2026

Net income

$312M

Latest quarter · Q3 2026

Quarterly net margin

10.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$28.56B
P/E
25.9
EPS
$10.04
Volume
648.93K
Daily trading
€217.95M
Dividend yield
1.29%

How Quest Diagnostics is changing

All results
  • Revenue grew 3.2% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 115% of net income

  • Shares outstanding down 16.9% in 5 years

Returns

Quest Diagnostics returns with dividends

$1,000 invested in Quest Diagnostics 5 years ago, on November 16, 2021, would be worth $1,947 today with dividends reinvested: +94.74% in total, +14.26% per year. On price alone it would be $1,768 (+76.81%).

PeriodQuest DiagnosticsS&P 500$1,000 becomes
1 month+11.35%−3.12%$1,114
6 months+40.23%+2.07%$1,402
Year to date+50.80%+10.46%$1,508
1 year+42.90%+13.33%$1,429
3 years+105.27%+67.73%$2,053
5 years+94.74%+60.86%$1,947
10 years+275.95%+247.35%$3,759

Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Quest Diagnostics: technical analysis

Quest Diagnostics is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.

Trend
Upward
RSI (14 sessions)
71
Above 70: a strong rise in a short time
vs 200-session average
+21.10%

Active signals

  • New 52-week high.

  • RSI above 70: the stock has risen a lot in a short time.

Support and resistance

Price areas where Quest Diagnostics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$261.68
  3. Support$248.01−5.22%2 touches, last on September 21, 2026
  4. Support$225.51−13.82%3 touches, last on October 21, 2026
  5. Support$213.35−18.47%2 touches, last on February 27, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
−0.07
Volatility (60 sessions, annualised)
21.9%
Largest fall in the last year
−11.94%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Quest Diagnostics: seasonality

Average monthly price change over 30 years

−0.6%Jan+0.2%Feb+2.0%Mar+6.8%Apr+2.9%May+2.8%Jun−0.6%Jul−0.2%Aug−0.7%Sep−0.1%Oct+3.4%Nov+2.3%Dec

Over the last 30 years, the strongest month for Quest Diagnostics has been April: +6.80% on average, positive in 20 years out of 30. The weakest has been September: −0.68% on average, positive in 12 years out of 30. November, the current month, has been positive in 24 years out of 29 (+3.36% on average).

Show chart data
MonthAverageMedianPositive years
January−0.56%−0.41%14 of 30
February+0.19%−0.63%13 of 30
March+1.98%+3.16%20 of 30
April+6.80%+2.78%20 of 30
May+2.86%+2.40%22 of 30
June+2.79%+1.83%20 of 30
July−0.57%−2.51%13 of 30
August−0.18%+0.34%17 of 30
September−0.68%−1.47%12 of 30
October−0.06%−0.06%15 of 30
November+3.36%+4.99%24 of 29
December+2.35%+0.85%20 of 29

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Quest Diagnostics and its competitors

Based in Secaucus, New Jersey, and operating since 1967, the company runs a network of laboratories and patient service centers that handles routine and advanced clinical tests, anatomic pathology, and genetic screening for prenatal care. Its services reach physicians, hospitals, patients, employers, insurers, and government agencies across the US, with brands including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum alongside its own name. Workplace drug testing, toxicology, and underwriting support for life insurers are among its offerings, and it also develops in vitro diagnostic tests.

Headquarters
Secaucus, United States
Employees
60,000
Founded
1967
Chief executive
James Davis
Quest Diagnostics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Quest DiagnosticsDGX$28.56B14.9%25.9+40.23%
Labcorp HoldingsLH$30.08B11.2%30.4+48.09%
IlluminaILMN$31.3B19.1%36.1+40.14%
Mettler-Toledo InternationalMTD$34.59B27.8%37.7+67.76%
Guardant HealthGH$20.52B-39.4%—+52.78%
Medpace HoldingsMEDP$19.12B21.4%38.0+57.36%

Same industry or related industries, similar size. Compare Quest Diagnostics with its competitors · Full profile